Ground Swell Capital’s Moderna MRNA Stock Holding History

Ground Swell Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,944	Closed	-$492K	–	103
2023 Q4	$492K	Buy	+4,944	New	+$416K	1.81%	13

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ground Swell Capital's MRNA Position: Q1 2024 in Review

Ground Swell Capital sold out of Moderna (MRNA) in Q1 2024, closing a stake of 4,944 shares — an estimated $492K sold.

Ground Swell Capital first reported a position in MRNA in Q4 2023 and held it in 1 quarter. The position peaked at $492K in Q4 2023. 902 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

Ground Swell Capital reported no remaining Moderna position as of Q1 2024 after selling out during the quarter.
Ground Swell Capital sold 4,944 Moderna shares in Q1 2024, an estimated $492K.
Ground Swell Capital first reported a position in Moderna in Q4 2023 and held it in 1 quarter.
Ground Swell Capital's Moderna position peaked at $492K in Q4 2023.
902 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Ground Swell Capital's 13F filing for Q1 2024, filed 14 May 2024.